Aktienanalyse zu Ultragenyx Pharmaceutical Inc (RARE)RAREUltragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company's clinical-stage pipeline consists of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its products include Crysvita (burosumab), Mepsevii (vestronidase alfa), Dojolvi (triheptanoin), and Evkeeza (evinacumab). Crysvita is used for the treatment of X-linked hypophosphatemia, or XLH, in adult and pediatric patients one year of age and older. Mepsevii is used for the treatment of children and adults with mucopolysaccharidosis VII, or MPS VII, also known as Sly syndrome. Dojolvi is used for the treatment of pediatric and adult patients severely affected by long-chain fatty acid oxidation disorders, or LC-FAOD. Evkeeza is used for the treatment of homozygous familial hypercholesterolemia, or HoFH. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ultragenyx Pharmaceutical Inc. (RARE) is a good buy right now due to its recent FDA accelerated approval for GENGLYCOS, which is expected to significantly enhance revenue potential. The current price is $25.61, and analysts have set price targets as high as $103, indicating substantial upside potential. Additionally, the gross margin stands at 84.11%, reflecting strong profitability potential despite current losses. However, the main risk is the negative net income, which was -92 million USD in the latest quarter, indicating ongoing financial challenges.

18 analysts cover RARE: 10 rate it Buy, 7 Hold and 1 Sell. The average price target is 61.65.